Chinese CRO Tigermed completes $80M IPO

Shanghai's Tigermed Consulting, a clinical-stage CRO, raised $80 million with its IPO on Shenzhen's ChiNext exchange, selling 13.4 million shares, ChinaBio Today reports. The company, founded in 2002, operates 39 offices across China and has inked partnerships with CrownBio, NovaSecta and Medidata Solutions ($MDSO). Report

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.